Abstract
The Exceptional Responders Initiative is a pilot study to investigate the underlying molecular factors driving exceptional treatment responses of cancer patients to drug therapies. Study researchers will examine molecular profiles of tumors from patients either enrolled in a clinical trial for an investigational drug(s) and who achieved an exceptional response relative to other trial participants, or who achieved an exceptional response to a non-investigational chemotherapy. An exceptional response is defined as achievement of either a complete response or a partial response for at least 6 months duration in a trial or treatment where the ove
Catalogue metadata
- Record ID
- AISLI-R-632A0C9F5D647FEF79D4
- Type
- Datasets
- Source catalogue
- registry.opendata.aws
- الموضوع
- 生命科学与生物医学
- شروط الاستخدام
- NIH Genomic Data Sharing Policy: https://gdc.cancer.gov/access-data/data-access-policies